Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.45 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.45 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7078818 | 0.94 | ALDH1A1 (0.54) | ALDH1A1LMNAMTNR1AMTNR1BATM | |
| SCHEMBL6928975 | 0.88 | ATM (0.57) | ALDH1A1LMNAMTNR1AMTNR1BATM | |
| SCHEMBL12685624 | 0.87 | MTNR1A (0.56) | ALDH1A1LMNAMTNR1AMTNR1BATM | |
| SCHEMBL3186828 | 0.84 | HDAC3 (0.59) | ALDH1A1LMNARAB9AHPGDPTGDR2 | |
| SCHEMBL6935056 | 0.84 | FAAH (0.48) | ALDH1A1LMNANPC1RAB9AALOX15 | |
| SCHEMBL7364397 | 0.84 | HDAC1 (0.57) | ALDH1A1NPC1RAB9APTGDR2TBXAS1 | |
| SCHEMBL13412642 | 0.84 | ALDH1A1 (0.50) | ALDH1A1LMNAMTNR1AMTNR1BATM | |
| SCHEMBL16334378 | 0.83 | ALDH1A1 (0.46) | ALDH1A1LMNANPC1RAB9AHPGD | |
| SCHEMBL5000520 | 0.83 | FAAH (0.46) | ALDH1A1LMNANPC1RAB9AALOX15 | |
| SCHEMBL19474670 | 0.82 | LTA4H (0.53) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020006922-A1 | N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors | AMERICAN CYANAMID COMPANY (US) | 2002-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020006922-A1 | N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors | MMP12, ADAM33, MMP2 | ALDH1A1 3024/4885LMNA 3266/4885MTNR1A 3805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.